Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
To find a better FTO-targeting drug, researchers searched a collection of 260,000 chemicals housed by NCI.
Author Suleika Jaouad’s new project helps people channel isolation into creativity and connection.
Hispanic blood cancer patients living at the U.S./Mexico border may have lower overall survival than those who live in other parts of Texas.
Starting palliative interventions at the onset of hospitalization for chemotherapy greatly improves quality of life.
In mouse study, gene-edited cells stay safe as immunotherapy attacks cancer
The drug may represent a “fundamental building block for new combinations that will hopefully have transformative potential.”
The findings hold particular promise for people who haven’t been helped by the targeted drug tagraxofusp.
Engineered T cells kept leukemia from returning in 12 high-risk patients.
The approvals amount to a “game-changer for how we think about treating different groups of patients with AML.”
Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
ASH 2018 conference highlights precision medicine, machine learning and gut microbiome.
The life-threatening side effect, called differentiation syndrome, is related to the acute myeloid leukemia medicine Idhifa (enasidenib).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.